Welcome to Pharm-Olam Insights

Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.

By Ibett Romero
On March 19, 2020

Phase I Oncology PD-1 Inhibitor Enrolled 78 Days Early

Pharm-Olam is a mid-sized, global CRO that provides clinical research solutions for rare diseases, oncology, hematology,...

(1 minute read)

Tags: Pharm-Olam Insights, Oncology-Hematology Disease

By Ryan Michalek
On March 11, 2020

Effective Cohort Management in Early Phase Oncology Trials

Cohort management is part and parcel of conducting dose-escalation studies, but not all teams effectively manage it....

(5 minute read)

Tags: Pharm-Olam Insights, Oncology-Hematology Disease

A white paper exploring COVID-19 research and its impact on global clinical research.

Welcome to Pharm-Olam Insights

The Pharm-Olam Insights Blog

Phase I Oncology PD-1 Inhibitor Enrolled 78 Days Early

Effective Cohort Management in Early Phase Oncology Trials

Join other Clinical Development experts to receive the latest industry news, trends and insights.